课题基金 / 基金详情

ACTG226--ORAL GANCICLOVIR IN HIV INFECTED CHILDREN WITH ASYMPTOMATIC CMV

ACTG226--ORAL GANCICLOVIR IN HIV INFECTED CHILDREN WITH ASYMPTOMATIC CMV
ACTG226——无症状 CMV 感染 HIV 儿童口服更昔洛韦
批准号：
6275289
负责人：
Ram Yogev
金额：
$2.26万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6275289
关键词：
AIDS therapy HIV infections Herpesviridae disease adolescence (12-20) child (0-11) clinical research clinical trial phase I cytomegalovirus dosage drug screening /evaluation drug tolerance ganciclovir human subject human therapy evaluation longitudinal human study oral administration pediatric AIDS pharmacokinetics

项目摘要

项目成果

Ram Yogev的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ACTG 226 is a Phase I, open-label, dose-escalating trial of oral ganciclovir in HIV-infected children aged 2 months to 20 years with asymptomatic cytomegalovirus (CMV) and low CD4 cell counts or with quiescent CMV disease. The purposes of this study are to evaluate the phamracokinetics, long-term safety and tolerance, and maximum tolerated dose of oral ganciclovir in HIV-infected patients, and to evaluate the effect or oral ganciclovir on the virologic parameters of CMV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Units for HIV/AIDS Clinical Trials Networks
Units for HIV/AIDS Clinical Trials Networks
Units for HIV/AIDS Clinical Trials Networks
Units for HIV/AIDS Clinical Trials Networks
海外基金